Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma

Genes and Immunity

Volumn 3, Issue 4, 2002, Pages 229-232

  Howell, V M ^a,b   Bateman, A C ^b   Turner, S J ^a   Collins, A ^a   Theaker, J M ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Malignant melanoma; SNPs; VEGF

Indexed keywords

VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ALLELE; ANGIOGENESIS; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; GENETICS; PATHOPHYSIOLOGY; SKIN TUMOR; SURVIVAL;

ENDOTHELIAL GROWTH FACTORS; HAPLOTYPES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LINKAGE DISEQUILIBRIUM; LYMPHOKINES; MELANOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 3242717786     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363851     Document Type: Article

References (22)

1. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
2. Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
3. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumour cells: consequences for tumour growth and metastasis. Cancer Metastasis Rev 1996; 15: 165-176.
4. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differently in normal tissues, macrophages and tumors. Mol Biol Cell 1992; 3: 211-220.
5. Freeman MR, Schneck FX, Gagnon ML. Peripheral blood lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-4145.
6. Bayer-Garner IB, Hough AJ, Smoller MD. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Pathol 1999; 12: 770-774.
7. Vlaykova T, Laurila P, Muhonen T et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9: 59-68.
8. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000; 82: 1528-1534.
9. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-1249.
10. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-1235.
11. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-448.
12. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV. Polymorphisms in vascular endothelial growth factor gene are associated with increased risk of acute rejection in renal transplant recipients. J Am Soc Nephrol 2002; 13: 260-264.
13. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2: 25-31.
14. Clark WH Jr, Elder DE, Guerry D IV et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989: 81: 1893-1904.
15. Mackie RM, Smyth JF, Soutar DS et al. Malignant melanoma in Scotland 1979-1983. Lancet 1985; 2: 859.
16. Mackie R, Hunter JA, Aitchison TC et al. Cutaneous malignant melanoma, Scotland, 1979-1983. The Scottish Melanoma Group. Lancet 1992; 339: 971-975.
17. Vollmer RT, Seigler HF. Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. Am J Clin Pathol 2001; 115: 205-212.
18. Collins A, Morton NE. Mapping a disease locus by allelic association. Proc Natl Acad Sci USA 1998; 95: 1741-1745.
19. Terwilliger JD, Ott J. Handbook of Human Genetic Linkage. The Johns Hopkins University Press; Baltimore, 1994.
20. Yue FY, Dummer R, Geertsen R et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630-637.
21. Zheng LM, Ojcius DM, Garaud F et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
22. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification and sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.